Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)

v3.21.2
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)
$ in Thousands
1 Months Ended 3 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Number of Operating Segments   2
Restructuring Charges, Total [1]   $ 1,185
Payments for Restructuring   0
Restructuring Reserve, Settled without Cash   $ 0
Diagnostics and Genomics [Member]    
Restructuring Charges, Total $ 1,200  
[1] The charges recorded above are accrued within Other current liabilities as of September 30, 2021. There were no cash payments or adjustments to the initial accrual during the period ended September 30, 2021.